Aurealis Therapeutics to present at Swiss Nordic Bio 2018

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company’s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018. The presentation is scheduled for: Time: Thursday, February 8th 2018 […]